...trading is slated for Thursday. The company comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...

...two biologics services companies: PolyTherics Ltd. and Antitope Ltd. Burt said the pair provide complementary services: PolyTherics...

...Exchange underwritten by Cenkos Securities plc. Abzena comprises two subsidiaries -- PolyTherics Ltd. and Antitope Ltd. PolyTherics...

...Abzena's PolyTherics Ltd. subsidiary partnered with Alpha Cancer to develop drug conjugates to treat cancer. PolyTherics will...
...has exclusive, worldwide rights to recombinant human AFP from Merrimack Pharmaceuticals Inc. (NASDAQ:MACK, Cambridge, Mass.). PolyTherics...

...Ltd. and said Abzena comprises two subsidiaries - PolyTherics and Antitope. The company will move PolyTherics'...
...Ltd., which continued to operate as a subsidiary of PolyTherics (see BioCentury, Aug. 5, 2013). PolyTherics...

...PolyTherics and MacroGenics extended a 2010 deal to develop antibody-drug conjugates (ADCs). Under the extension, PolyTherics...
...original deal, PolyTherics used its TheraPEG technology to extend the half-life of the DART antibodies. PolyTherics...
...technology to develop resulting antibodies. PolyTherics is eligible for undisclosed milestones, plus single-digit percentage royalties. PolyTherics...

...Annexon partnered with PolyTherics' Antitope Ltd. subsidiary to generate antibodies to treat neurodegenerative diseases. Annexon will...
...developed. The partners declined to disclose financial details. Annexon Inc. , South San Francisco, Calif. PolyTherics Ltd....

...Spirogen's ADC technology: the Genentech Inc. unit of Roche , Seattle Genetics, Ablynx N.V. and PolyTherics Ltd....
...NYSE:AZN), London, U.K. Genentech Inc. , South San Francisco, Calif. MedImmune LLC , Gaithersburg, Md. PolyTherics Ltd....

...PolyTherics and Tube partnered to develop antibody-drug conjugates (ADCs) to treat cancer using PolyTherics' ThioBridge conjugation...
...to develop in-house. The partners also plan to conduct preclinical testing of ADC candidates that PolyTherics...
...revenues arising from licensing deals but declined to disclose financial terms (see BioCentury, Aug. 5). PolyTherics Ltd....

...to serve as a conjugation point for cytotoxic agents. Another company in this space is PolyTherics Ltd....
...Cambridge, Mass. Millennium Pharmaceuticals Inc. , Cambridge, Mass. Pfizer Inc. (NYSE:PFE), New York, N.Y. PolyTherics Ltd....
...for non-covalent conjugation of peptide linked to a payload NA (drug discovery not started yet) PolyTherics Ltd....